Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 25 2022 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2022
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form
40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This Form 6-K is hereby incorporated by reference
into the registrant’s Registration Statements on Form S-8 (File No. 333-229163 and 333-248479) and Form F-3 (File No. 333-228054
and 333-238731), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports
subsequently filed or furnished.
On March 25, 2022, CollPlant Biotechnologies Ltd.
(the “Company”) announced that on May 2, 2022, it will hold at the offices of Gross & Co. law firm, at One Azrieli Center,
Round Building, 40th Floor, Tel-Aviv, Israel, an annual and extraordinary general meeting of shareholders (the “General Meeting”)
at 10:00 a.m. Israel time. In connection with the meeting, the Company furnishes the following documents:
| 1. | A
copy of the Notice and Proxy Statement with respect to the Company’s General Meeting describing the proposals to be voted upon
at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached
hereto as Exhibit 99.1; and |
| 2. | A
form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto
as Exhibit 99.2. |
Exhibit Index
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD. |
|
|
|
Date: March 25, 2022 |
By: |
/s/ Eran Rotem |
|
|
Name: |
Eran Rotem |
|
|
Title: |
Deputy CEO and Chief Financial Officer |
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024